I think based on further reading into anp over the weekend.
A combination trial may occur between serepta and anp.
I would like to see a partnership with all associated costs of ema and fda trials on the new "partner" following with a large payment for licensing upon commercialisation and royalties.
Similar to Novartis and MSB. With a much better outcome
Research note, page-83
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.010(8.70%) |
Mkt cap ! $112.6M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $371.5K | 2.964M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 166075 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 88000 | 1 |
View Market Depth
| Last trade - 13.51pm 11/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |